Navigation Links
Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
Date:10/7/2008

Executive Officer, Bavarian Nordic A/S, said "We are delighted with these promising results from this Phase II study, which will be published in full over the coming months. Based on these data we believe that PROSTVAC(TM) offers a potential breakthrough and real hope for patients suffering from advanced prostate cancer. Furthermore, unlike other current prostate cancer vaccines in development, PROSTVAC(TM) is an off-the shelf product that does not require complex individualised therapy. These results provide a full endorsement for our decision to strengthen our presence in cancer vaccine research, as announced earlier this year in connection with our newly launched strategy."

This announcement does not change Bavarian Nordic's previously announced financial guidance for 2008. The decision to take PROSTVAC(TM) into phase III trials will have a limited financial impact on year 2009, which will be covered by the company's net free liquidity.

Asger Aamund

Chairman

Conference call

A conference call will be held today, 7 October 2008 at 10:30 am (CEST). Anders Hedegaard, President & CEO and Reiner Laus MD and CEO of BN ImmunoTherapeutics Inc. will present. The accompanying presentation will be available on the company's website: http://www.bavarian-nordic.com in advance.

Dial-in numbers for the conference call are:

UK: +44(0)20-7162-0025,

US: +1-334-323-6201.

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no oblig
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Bavarian Nordic Enters Clinical Trials with HIV Multiantigen Vaccine
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... St. Jude scientists, findings in ataxia telangiectasia-like ... into the links between brain disease and ... Tenn., Jan. 14 Scientists ... teased apart the biological details distinguishing two ...
... first quarterKENILWORTH, N.J., Jan. 14 Schering-Plough Corporation (NYSE: ... Food and Drug Administration (FDA) has issued a complete ... acute treatment of schizophrenia in adults and in the ... bipolar I disorder in adults as monotherapy. The ...
Cached Medicine Technology:Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 2Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 3U.S. FDA Issues Complete Response Letter for SAPHRIS(TM) (ASENAPINE) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder 2
(Date:7/10/2014)... Up to 70% of Parkinson,s disease (PD) patients ... of life. Some patients have disturbed sleep/wake patterns ... while other patients may be subject to sudden ... PD patients may exhibit REM-sleep behavior disorder (RBD), ... even before motor symptoms appear. A review in ...
(Date:7/10/2014)... the human brain operates much the same whether active ... a better understanding of schizophrenia, bipolar disorder and other ... million Americans. , In newly published research in the ... at the Center for Molecular and Behavioral Neuroscience, determined ... rest is basically the same as that of a ...
(Date:7/10/2014)... Manchester scientists have shown that a new drug could prove ... aggressive form of lung cancer. , Scientists from the Cancer ... and part of the Manchester Cancer Research Centre, teamed up ... in 2010, to test a drug known as AZD3965 ... published in the journal Clinical Cancer Research , also ...
(Date:7/9/2014)... July 10, 2014 For the first time, researchers ... Aboriginal population in Canada uses health care. A new ... to clearly demonstrate the unique challenges faced by urban ... St. Michael,s Hospital. , The findings, published today ... urban First Nations individuals and the general population. , ...
(Date:7/9/2014)... hidden ways that cells are regulated, scientists at Rockefeller ... cells more likely to metastasize. , What,s more, the ... blocking two other proteins that are normally linked to ... could have unexpected ties. , The study, which ... , points to the possibility of new cancer therapies ...
Breaking Medicine News(10 mins):Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:Working to loosen the grip of severe mental illness 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3
... Alzheimer's disease and is connected to the same brain pathology. There ... cognitive decline the loss of memory and certain other aspects of ... a normal part of aging, others that it is an early ... it's a disease in its own right. ,A new ...
... the combination of just two genes, according to a new study ... of Clinical Endocrinology and Metabolism this week,// identifies one gene on ... height in men. These genes may also help explain why men ... of both of these genes you will be taller than a ...
... serum concentrations of estrogen and testosterone have about twice ... relatively low serum concentrations of these sex hormones. Associations ... breast cancer were not different in women who donated ... levels in these women were not a preclinical finding. ...
... A new US research has found that young women are ... young men.The study, which contradicts the stereotype that men// are ... The Annals of Internal Medicine this week. ,Researchers from ... years after they were discharged from hospital after a heart ...
... the liver from damage, according to new research from ... laboratory rats. //The rats were then given D-galactosamine, a ... synthesis and results in cell death. The rats fed ... ,The Researchers discovered three new compounds that might ...
... drugs called statins may reduce their risk of developing ... to offer// powerful protection against heart disease for people ... evidence to date that statin drugs may also help ... smaller study had suggested these drugs might offer some ...
Cached Medicine News:
A system for the removal and filtration of laser and surgical smoke....
The FreedomAire Surgical Helmet System is a lightweight, comfortable helmut system with superior air flow, and a removable motor module that lifts off for easy cleaning....
...
... contains these disposable, silver/silver chloride ... separated into eight tabs), two ... patient use only. Starter kit ... red and black, one green ...
Medicine Products: